Looks like you’re on the UK site. Choose another location to see content specific to your location
Roche reports positive idiopathic pulmonary fibrosis data for Esbriet
Roche has announced the results of a retrospective data analysis that highlights the benefits offered by its drug Esbriet in the treatment of idiopathic pulmonary fibrosis (IPF).
Three post-hoc analyses of the pooled phase III ASCEND and CAPACITY studies have offered evidence that IPF patients treated with Esbriet may experience a reduction in the risk of death and patient-reported breathlessness compared to placebo, as well as fewer respiratory-related hospitalisations.
In a fourth real-world study of US claims data on persistency, Roche's drug was also associated with good adherence rates, with 76.2 percent of Esbriet patients persisting with the treatment.
IPF is a fatal disease caused by irreversible, progressive scarring of the lungs, which makes breathing difficult and starves other vital organs of oxygen. It is characterised by more rapid declines than most forms of cancer, with a recent study showing that only people with lung and pancreatic cancer have worse survival rates.
Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "This data expands our understanding of how Esbriet may help people with IPF by slowing disease progression. The data also provides insights on management of IPF in real-world settings."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard